Every 10-Q that Plexus Corp (PLXS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PLXS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PLXS filings page.
Plexus Corp. reported strong top-line growth for the quarter ended July 4, 2026, with net sales of $1,304.8 million, up 28.1% year over year, and nine‑month sales of $3,538.4 million, up 19.0%. Gross margin held at 10.1%. Operating income rose to $61.3 million, but operating margin slipped to 4.7% as selling and administrative expenses increased, driven largely by $20.5 million of stock‑based compensation in the quarter, including $12.9 million from accelerated vesting tied to executive retirements. Net income was $43.0 million versus $45.1 million a year earlier, and diluted EPS was $1.58 versus $1.64, as the effective tax rate climbed to 23.8% due to a new global minimum tax and the absence of a prior‑year discrete tax benefit. For the first nine months, net income rose to $134.0 million and diluted EPS to $4.90.
Growth was broad-based: AMER and APAC sales increased 37.2% and 30.4% in the quarter, while Industrial and Aerospace/Defense sectors grew 42.2% and 27.1%. Cash and restricted cash were $314.6 million and total debt, finance lease and other obligations were $275.5 million. Operating cash flow was $39.0 million and free cash flow was negative $35.3 million, reflecting higher inventories to support program ramps and increased accounts receivable. The company repurchased 341,799 shares for $63.6 million under its 2026 authorization, with $21.4 million of capacity remaining, and reported after‑tax ROIC of 14.9% versus a 9.0% WACC.
Plexus Corp. delivered strong growth for the quarter ended April 4, 2026. Net sales rose to $1.16 billion from $980.2 million, an 18.7% increase, driven by higher demand across AMER, APAC and EMEA regions and all three market sectors.
Net income increased to $49.8 million from $39.1 million, with diluted EPS up to $1.82 from $1.41. Gross margin edged up to 10.2% and operating margin to 5.3%, helped by higher volumes and favorable mix despite higher fixed and compensation costs.
Cash generation weakened as operating cash flow fell to $13.1 million from $90.3 million, largely due to higher inventories and other working capital uses, resulting in free cash flow of negative $34.6 million. The company ended with $303.2 million in cash and $234.1 million of debt and spent $43.0 million repurchasing 262,092 shares, with $42.0 million remaining under its current buyback authorization.
Plexus Corp. reported fiscal Q1 2026 net sales of $1.07 billion, up about 10% from $976.1 million a year earlier, driven mainly by stronger demand in the AMER region and the Healthcare/Life Sciences sector.
Net income rose to $41.2 million from $37.3 million, with diluted EPS increasing to $1.51 from $1.34. Gross margin slipped to 9.9% from 10.3% as higher fixed costs offset some of the sales growth, while operating margin improved to 5.1% from 4.8% helped by lower restructuring charges.
Free cash flow was negative $50.6 million as the company invested in inventory to support program ramps and raised capital spending. Plexus ended the quarter with $249.4 million in cash and cash equivalents and $158.0 million in debt, finance lease and other financing obligations, and repurchased 152,987 shares for $22.4 million under its 2026 buyback program.